Reverse Merger to Enter Nasdaq

Slate Medicines and Fulcrum Therapeutics (FULC) entered into a definitive merger agreement on August 17, 2026, involving a full stock-for-stock transaction. The deal, subject to shareholder and regulatory approvals, is expected to close in the fourth quarter of 2026, with the combined entity operating as Slate Medicines and trading on Nasdaq under the ticker symbol SLTE. Existing Fulcrum shareholders will hold 5% of the combined company, while Slate shareholders and private investors will hold 95%, effectively constituting a reverse merger of Slate. This transaction aims to redeploy Fulcrum's cash and public listing, which were being strategically re-evaluated after the discontinuation of the pociredir program for sickle cell disease, towards Slate's migraine platform.

$245 Million PIPE and Shareholder Value Distribution

Concurrently with the closing of the merger, Slate secured a $245 million private investment (PIPE) led by Frazier Life Sciences, with participation from Forbion, RA Capital Management, and OrbiMed. This investment involves the acquisition of shares in the combined entity, rather than upfront payments or milestone payments from licensing agreements. Combined with Fulcrum's $20.3 million in net cash, this provides funding through 2029. Prior to closing, Fulcrum will distribute approximately $270 million in special cash dividends to existing shareholders. This structure provides ample cash runway for an early-stage company while returning the majority of excess cash directly to Fulcrum shareholders.

PACAP and VIP Dual-Targeting Clinical Strategy

SLTE-1009, which has not yet been branded, is a half-life-extended monoclonal antibody that combines and neutralizes pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP). This clinical-stage candidate has received approval to enter a Phase 1 clinical trial in Australia, with initial safety and pharmacokinetic data in healthy adults expected in mid-2027, followed by a Phase 2 dose-exploration study in migraine patients. The design aims to differentiate itself from competing therapies that primarily involve intravenous administration by enabling once-quarterly subcutaneous administration, thereby improving convenience and accessibility for patients. The program has not yet reached the FDA, EMA, or PMDA approval or advisory committee (AdComm) review stages.

Competitive Landscape and Market Potential

The current standard of care in the prophylactic market includes Aimovig (erenumab-aooe, CGRP receptor), Ajovy (fremanezumab-vfrm, CGRP), and Emgality (galcanezumab-gnlm, CGRP), all approved by the FDA in 2018, as well as the oral agent Qulipta (atogepant, CGRP receptor). H. Lundbeck's bocunebart (Lu AG09222, PACAP antibody), a direct competitor, met its primary endpoint in the Phase 2b PROCEED trial in February 2026, clinically validating the PACAP pathway. The global migraine prevention market is projected to grow from $2.95 billion in 2025 to $6.41 billion in 2033. The follow-up candidate, SLTE-2100, is a dual-targeting antibody that targets both PACAP/VIP and CGRP, and is in the lead optimization stage, with clinical entry planned for the second half of 2027 and development through a Phase 2a trial. This expansion of the portfolio, targeting patients with insufficient response to single-pathway therapies, is a key value proposition.